Aslan Pharmaceuticals | TalkMarkets

Latest Posts

Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO

Article By: ChinaBio® Today

Saturday, March 16, 2024 2:40 PM EDT

BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Also, Boehringer Ingelheim acquired an option to license drug candidates that treat symptoms of schizophrenia.

In this article: SOLTF, ASLN, REGMF, WUXIF, HNSPF

Read

Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO

Article By: ChinaBio® Today

Saturday, December 7, 2019 5:15 PM EDT

Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.

In this article: AZN, JNJ, MRK, CASI, ASLN

Read

Aslan Soars 186% After Journal Reports New Acute Myeloid Leukemia Data

Article By: The Fly

Saturday, November 23, 2019 11:10 AM EDT

Aslan Pharmaceuticals announced that new preclinical data characterizing ASLAN003 as a potential treatment for acute myeloid leukemia has been published in the November issue of Haematologica Journal which sent shares surging higher.

In this article: ASLN

Read

Week In Review: BeiGene's BTK Inhibitor Approved In US And China Approval For PD-1 Expected In Two Months

Article By: ChinaBio® Today

Saturday, November 16, 2019 4:09 PM EDT

Beijing's BeiGene had an outstanding week: its BTK drug, Brukinsa™, was approved for US use to treat mantle cell lymphoma, and its PD-1 candidate is poised for China approval before the end of the year to treat classical Hodgkin’s lymphoma.

In this article: HCM, BGNE, ASLN

Read